Skip to main content
. 2015 Jun 12;10:951–961. doi: 10.2147/CIA.S69278

Figure 2.

Figure 2

CLL11 trial progression-free survival.

Notes: From The New England Journal of Medicine, Goede V, Fischer K, Busch R, et al, Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions, 370(12), 1101–1110. Copyright © 2014 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.45

Abbreviations: CI, confidence interval; G-Clb, obinutuzumab-chlorambucil; R-Clb, rituximab-chlorambucil.